This inventor holds 1 USPTO granted patent. Top assignee: Aventis Pharma Deutschland, Gmbh. Active years: 2005.
Company Filing History:
Years Active: 2005
Title: Jörg Habermann: Innovator in Collagenase Inhibition
Introduction
Jörg Habermann is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that selectively inhibit collagenases. His work has implications for the treatment of various diseases associated with increased activity of matrix metalloproteinase 13.
Latest Patents
Jörg Habermann holds a patent for "Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases." This patent describes compounds that possess the ability to selectively inhibit collagenase (MMP), which may be beneficial in both prophylaxis and therapy for diseases characterized by heightened collagenase activity.
Career Highlights
He is currently employed at Aventis Pharma Deutschland GmbH, where he continues to engage in innovative research. His work at the company has allowed him to explore the therapeutic potential of his patented compounds further.
Collaborations
Throughout his career, Jörg has collaborated with esteemed colleagues such as Klaus-Ulrich Weithmann and Herbert Kogler. These collaborations have enriched his research and contributed to the advancement of his projects.
Conclusion
Jörg Habermann's contributions to the field of collagenase inhibition highlight his role as an important inventor in biochemistry. His patented compounds offer promising avenues for therapeutic development, showcasing the impact of his work in the medical field.